Makale detayı · 2017
Sclerostin and bone metabolism markers in hyperthyroidism before treatment and interrelations between them
- Yıl
- 2017
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Acta Biochimica Polonica
- Katalog eşleşmesi (ISSN) Acta Biochimica Polonica
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
Sclerostin is a glycoprotein that is produced by osteocytes and reduces the formation of bones by inhibiting Wnt signal pathway. Thyroid hormones are related with Wnt signal pathway and it has been reported that the increasing thyroid hormones in hyperthyroidism fasten the epiphysis maturation in childhood, increase the risk of bone fractures by stimulating the bone loss in adults. The aim of this study is examining the sclerostin serum levels, the relation between sclerostin and thyroid hormones and the biochemical markers of bone metabolism in patients with hyperthyroidism whose treatments have not started yet. No difference was found in the serum sclerostin levels between the hyperthyroidism group and the control group (p=0.452). The serum osteocalcin levels and 24-hour urinary phosphorus excretion were found to be higher in the hyperthyroid group than the control group (p<0.001, p=0.009). A positive correlation (p<0.001) was determined between the sclerostin and bone Alkaline phosphatase levels; a negative correlation (p<0.05) between the osteocalcin and thyroid stimulating hormone (TSH); a positive correlation (p<0.001, p<0.001) between the osteocalcin and thyroid hormones (FT3 , FT4); and a positive correlation (p<0.001) between the deoxypyridinoline and hydroxyproline. No correlation was determined between sclerostin and TSH, FT3, FT4 (p>0.05). We are considering that a long-term study that covers the pre-treatment and post-treatment periods in hyperthyroidism patients, and the search during destruction and construction periods of the skeleton mineralization would be more enlightening; and the assessment of the synthesis of the sclerostin in bone tissue and in the serum level might show differences.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
10 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 4 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism 2024
- Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism 2024
- Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism 2024
- Evaluation of Bone Turnover Markers Such as Osteoprotegerin, Sclerostin and Dickkopf-1 in Subclinical Hyperthyroidism 2022